Atezolizumab
分子量：144.59KD
简介：Atezolizumab 是一种人源化单克隆抗体 IgG1，抵抗程序性死亡因子配体1 (PD-L1)，用于癌症研究。
产品形式：蛋白原液。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
质量标准：
Non-reduced CE-SDS:………………………………………….>90%;
SEC-HPLC:………………………………………………………….>95%;
Bacterial Endotoxins Test：…………………………………. .<10EU/ml
Residual Proteins of Host Cell: ……………………………. <100 ng/mg
Exogenous residual DNA: …………………………………. . <100pg/mg
Residual Protein A: ……………………………………………. .<100 ng/mg
Biological Activity:………………………………………….……. .80% to 125% of standard
储存条件：-70 ± 15℃for long-term storage, 2-8℃for short-term storage, away from light.
运输条件：干冰运输
使用建议：
meilunbio提供的产品为蛋白原液形式。每种装于冻存管中，单抗质量为标示数量1MG或者5MG，体积根据其浓度不同略有不同。
使用前可以根据自己实验需求进行稀释，溶剂建议用去离子无菌水(meilunbio货号MA0028，去离子无菌水(细胞培养用水))或者PBS（meilunbio货号MA0015PBS(1X),细胞培养级）。
不建议使用含有防腐成分的稀释液进行稀释，会增加细胞或者动物毒性。
稀释前，计算加入多少体积溶剂，请参考购买批次质检单上蛋白浓度，或者询问我司，
举例，质检单显示该批次单抗蛋白原液蛋白浓度为 50mg/ml
对应5MG包装的蛋白原液体积为5mg（质量）/50mg/ml(浓度)=0.1ML，
实验需求蛋白浓度为10mg/ml, 需要稀释倍数为 50/10=5, 则需要加入0.4ML,即400ul PBS或者无菌去离子水即可。
若给药量为固定质量值，比如单次给药0.5MG，对应蛋白原液给药体积为10ul，建议稀释后，提高给药体积降低误差，因为注射器或者移液器吸头残留会影响实验效果。
稀释后的蛋白溶液，可于2-8度冷藏避光保存不超过2周，不建议长期储存。
避免反复冻融，每次冻融蛋白活性会降低约5%左右。
生物活性（仅来自于公开文献，不保证其有效性）
|
描述
|
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. |
|
靶点 |
PD-L1 |
|
Description |
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). |
美仑相关产品推荐(更多相关靶点抑制剂请详询官网或客服)
|
产品编号
|
品名. |
Target |
|
MB2806 |
aflibercept |
VEGFR |
|
MB2786 |
Alemtuzumab |
CD52 |
|
MB2787 |
Alirocumab |
PCSK9 |
|
MB2789 |
Avelumab |
PDL-1 |
|
MB2784 |
Adalimumab |
TNF-α |
|
MB2791 |
Bevacizumab |
VEGF |
|
MB2792 |
Cetuximab |
EGFR |
|
MB2803 |
Daratumumab |
CD38 |
|
MB2794 |
Denosumab |
RANK Ligand |
|
MB2023 |
Eculizumab |
补体蛋白(C5) |
|
MB2795 |
Etanercept |
TNF |
|
MB2797 |
Evolocumab |
PCSK9 |
|
MB2773 |
Infliximab |
TNF-α |
|
MB2769 |
Ipilimumab |
CTLA-4 |
|
MB2772 |
Matuzumab |
EGFR |
|
MB2766 |
Mepolizumab |
IL-5 |
|
MB2767 |
Nivolumab |
PD-1 |
|
MB2774 |
Obinutuzumab |
CD20 |
|
MB2776 |
Ofatumumab |
CD20 |
|
MB2777 |
Omalizumab |
IgE |
|
MB2781 |
Panitumumab |
EGFR |
|
MB2761 |
Pembrolizumab |
PD-1 |
|
MB2762 |
Pertuzumab |
HER2 |
|
MB2763 |
Ranibizumab |
VEGFR |
|
MB2938 |
Ramucirumab |
VEGFR |
|
MB2749 |
Rituximab |
CD20 |
|
MB2757 |
Secukinumab |
IL-17 |
|
MB2751 |
Tocilizumab/Atlizumab |
IL-6 receptor |
|
MB2753 |
Trastuzumab |
ErbB2 |
|
MB2758 |
Ustekinumab |
IL-12 |
用途及描述：仅供科研，严禁用于人体(For R&D Only)
备注：库存情况可能有所变动，请与我们销售人员确认为准，价格情况请直接联系我们销售人员。